The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The KRAS G12C inhibitor MK-1084 for KRAS G12C–mutated advanced colorectal cancer (CRC): Results from KANDLELIT-001.
 
Iwona Lugowska
Honoraria - Agenus; Amgen; AstraZeneca; BeiGene; BMS; Celon Pharma; Cullinan Oncology; Jacobio; Janssen; Loxo; Macrogenics; Menarini; MSD; Pfizer; Rhizen Pharmaceuticals; ROCHE; Sanofi; Sanofi; Takeda
Research Funding - AGENUS (Inst); ROCHE (Inst)
 
Matteo Simonelli
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Incyte; Naya Oncology; SERVIER
Travel, Accommodations, Expenses - Pfizer; Pfizer; Pfizer; Roche; Sanofi
 
Junli Xue
Research Funding - Merck Sharp & Dohme (Inst)
 
Adrian Sacher
Research Funding - Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Bridgebio (Inst); CRISPR Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Hotspot Therapeutics (Inst); Iovance Biotherapeutics (Inst); Lilly Loxo (Inst); Merck (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; Genentech/Roche; Merck
(OPTIONAL) Uncompensated Relationships - Amgen; Genentech/Roche; Merck
 
Anastasios Stathis
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Debiopharm Group (Inst); Incyte; Incyte (Inst); Janssen Oncology (Inst); Loxo/Lilly (Inst); Novartis (Inst); Roche (Inst)
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BMS GmbH & Co. KG (Inst); BMS GmbH & Co. KG (Inst); Cellestia Biotech (Inst); Debiopharm Group (Inst); Incyte (Inst); Lilly (Inst); Loxo (Inst); MEI Pharma (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Prelude Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Incyte (Inst)
 
Rafal Dziadziuszko
Honoraria - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; MSD Oology; Pfizer; Roche/Genentech
Consulting or Advisory Role - GlaxoSmithKline
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Pfizer
 
Joon Oh Park
Consulting or Advisory Role - ABL Bio; Adicet Bio; Arcus Biosciences; AstraZeneca; Celgene; ImmuneOncia; Intocell; MediRama; Merck Serono; SERVIER
Research Funding - ABL Bio; Celgene; Eutilex; medpacto; SERVIER
Travel, Accommodations, Expenses - Minneamrita Therapeutics
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Abbvie; Affimed Therapeutics; AstraZeneca; Basilea; Bayer; BMS; Ellipses Pharma; Janssen Oncology; Merck; Roche
Speakers' Bureau - Bayer; Pierre Fabre
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); ADC Therapeutics (Inst); Amgen (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); Biomea Fusion (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Crescendo Bioscience (Inst); Cullinan Oncology (Inst); E-therapeutics (Inst); Eisai (Inst); F-Star Biotechnology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Grey Wolf Therapeutics (Inst); hemavant (Inst); HiFiBiO Therapeutics (Inst); Janssen (Inst); Kinnate Biopharma (Inst); Menarini (Inst); Merck (Inst); MonTa Biosciences (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Revolution Medicines (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
Other Relationship - BMS
 
Yu-Min Yeh
Research Funding - Merck Sharp & Dohme (Inst)
 
Mehmet Sendur
Honoraria - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; MSD; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - Abdi Ibrahim; Abdi Ibrahim; Amgen; Astellas Pharma; Bristol-Myers Squibb; Janssen; Novartis; Pfizer; Roche; Takeda
 
Harvey Yu-Li Su
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Merck Serono; MSD Oncology
Travel, Accommodations, Expenses - Merck KGaA
 
Christian Caglevic
Consulting or Advisory Role - Gilead Sciences
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Athenex (Inst); Bayer HealthCare Pharmacuticals (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Cogent Biosciences (Inst); daiichi Sankyo INC (Inst); Dizal Pharma (Inst); Exelixis (Inst); F. Hoffmann LaRoche (Inst); GlaxoSmithKline (Inst); Merck Sharp & Dohme (Inst); Merus; Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst); Sanofi (Inst); Zymeworks (Inst)
 
Rui-Hua Xu
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; Hutchison MediPharma; Junshi Pharmaceuticals; Keymed Biosience; MSD; QiLu Pharmaceutical
 
Ruth Perets
Employment - Rambam Health Care Campus
Honoraria - GlaxoSmithKline
Consulting or Advisory Role - 1E Therapeutics; GalMed Pharmacueticals; Simplivia
Research Funding - 1E Therapeutics
 
Elizabeth Ahern
Honoraria - MSD Oncology
Research Funding - Amgen (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No. 62/775803
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb
 
Abhijit Pal
Consulting or Advisory Role - Novotech
Travel, Accommodations, Expenses - MSD
Other Relationship - AstraZeneca; Pfizer
 
Thomas Jemielita
Employment - Merck
Stock and Other Ownership Interests - Merck
 
L. Rhoda Molife
Employment - MSD
Stock and Other Ownership Interests - Merck
 
Yewon Choi
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
Carlos Rojas
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Knight Therapeutics/Biotoscana; Merck Sharp & Dohme; Pfizer; Roche
Research Funding - AstraZeneca; Bristol-Myers Squibb/Celgene; Knight Therapeutics/Biotoscana; Merck; Pfizer; Roche
Expert Testimony - AstraZeneca; Bristol-Myers Squibb; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb